Major Depressive Disorder (MDD) Clinical Trial
Official title:
The Effects of Dopamine on Reward Processing
The purpose of this study is to evaluate the effects of a single low dose of the D2/D3
antagonist amisulpride on reward processing. More generally, this study will test the role of
dopamine (a naturally occurring brain chemical) in depression.
Hypotheses:
Administration of a single low dose of the D2/D3 antagonist amisulpride will (1) improve
performance in a behavioral task assessing learning from feedback and (2) boost activation in
reward-related brain regions.
Through an integration of a functional magnetic resonance imaging (fMRI) approach coupled
with a pharmacological challenge, the goal of the current study will be to investigate the
role of dopamine in MDD. Participants in this research will include 36 MDD subjects and 36
demographically matched healthy participants recruited from the community by Dr. Pizzagalli's
laboratory at McLean Hospital's Center for Depression, Anxiety and Stress Research. This
study will include two sessions:
- The first session will involve a diagnostic interview, and a series of questionnaires
and assessments.
- The second session will take place at the McLean Hospital's Neuroimaging Center, and
include the administration of a low-dose of amisulpride (50 mg capsule) or placebo,
followed by an fMRI brain scan and administration of two behavioral tasks.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00316160 -
Sexual Functioning Study With Antidepressants
|
Phase 4 | |
| Completed |
NCT05416957 -
Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
|
Phase 1 | |
| Active, not recruiting |
NCT03642964 -
A Study in Patients With Major Depressive Disorder
|
Phase 2 | |
| Terminated |
NCT01111565 -
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
|
Phase 3 | |
| Completed |
NCT01912196 -
Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)
|
Phase 2 | |
| Completed |
NCT00958204 -
Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression
|
Phase 3 | |
| Completed |
NCT00102492 -
Study Of GW679769 In Major Depressive Disorder
|
Phase 2 | |
| Completed |
NCT02012218 -
Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy
|
Phase 3 | |
| Completed |
NCT01477203 -
Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders
|
Phase 4 | |
| Completed |
NCT00768430 -
Optimization of IV Ketamine for Treatment Resistant Depression
|
Phase 2 | |
| Completed |
NCT00559299 -
Patient Tolerability Study of GSK163090
|
Phase 1 | |
| Terminated |
NCT01123707 -
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
|
Phase 3 | |
| Completed |
NCT04403373 -
Effectiveness of Walking Exercise in Improving Depression in Older Adults With Major Depressive Disorder, A Pilot Study
|
N/A | |
| Completed |
NCT05541302 -
Retrospective TMS Therapy for Adults With MDD
|
||
| Not yet recruiting |
NCT06385405 -
Electroencephalography-based Precise Repetitive Transcranial Magnetic Stimulation Treatment
|
N/A | |
| Completed |
NCT00330616 -
Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan
|
Phase 2 | |
| Recruiting |
NCT03012724 -
Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)
|
N/A | |
| Not yet recruiting |
NCT02395263 -
Comparison of Yuxintine With Placebo in Treatment of MDD
|
Phase 2 | |
| Completed |
NCT02380066 -
Comparison of Anyu Peibo With Placebo in Treatment of MDD
|
Phase 2 | |
| Completed |
NCT01187407 -
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
|
Phase 3 |